EI
DNLI icon

EAM Investors’s Denali Therapeutics DNLI Stock Holding History

EAM Investors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-26,214
Closed -$2.2M – 365
2020
Q4 		$2.2M Sell
26,214
-14,973
-36% -$905K 0.36% 92
2020
Q3 		$1.48M Buy
+41,187
New +$1.24M 0.35% 110

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM Investors's DNLI Position: Q1 2021 in Review

EAM Investors sold out of Denali Therapeutics (DNLI) in Q1 2021, closing a stake of 26,214 shares — an estimated $2.2M sold.

EAM Investors first reported a position in DNLI in Q3 2020 and held it in 2 quarters. The position peaked at $2.2M in Q4 2020. 216 funds tracked by Wall St. Rank hold DNLI as of Q1 2021.

  • EAM Investors reported no remaining Denali Therapeutics position as of Q1 2021 after selling out during the quarter.
  • EAM Investors sold 26,214 Denali Therapeutics shares in Q1 2021, an estimated $2.2M.
  • EAM Investors first reported a position in Denali Therapeutics in Q3 2020 and held it in 2 quarters.
  • EAM Investors's Denali Therapeutics position peaked at $2.2M in Q4 2020.
  • 216 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2021.

Based on EAM Investors's 13F filing for Q1 2021, filed 11 May 2021.